Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME of BMS-986196 in Healthy Males
NCT05981963Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2023
- Primary completion
- Oct 2023
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 11c-bms-986196 in multiple sclerosis (MS), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration of Total Radioactivity, Time of maximum observed plasma concentration of Total Radioactivity and 7 more. Started Aug 2023; status: completed.
02
Drugs
11c-bms-986196
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05981963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05981963.